Cell Therapy

T Cell Engineering Research and Development Exosomes Gene-Modified Therapies Transplantation Clinical Trials Immunotherapy Autoimmune Diseases Immune System Regenerative Medicine Pharmaceutical Research Stem Cell Research CAR-T Technology Manufacturing Challenges CAR T-cell Technology Genetic Engineering CAR-T Therapy Research Infrastructure T-cell Therapy T-Cell Reprogramming

3 ARTICLES

2mo ago

Engineered PRAME T Cells Produce One-Year Remission in Teen With Metastatic Kidney Cancer

Investigators say the one-year remission shows that TCR‑engineered cells targeting an intracellular antigen can clear some solid tumors, prompting a planned Phase I/II pediatric trial in 2027.

4 ARTICLES

5mo ago

Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

3 ARTICLES

5mo ago

Gilead Closes $7.8 Billion Arcellx Deal to Take Full Control of Anito‑cel

4 ARTICLES

7mo ago

C-Further Launches First Pediatric Cancer Programs, Taps MiNK for PRAME iNKT Therapy

7 ARTICLES

8mo ago

Johnson & Johnson to Build $1 Billion Cell Therapy Plant in Pennsylvania